DCVC Bio — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
BiotechData & InfrastructureEnterprise SoftwareMedia & EntertainmentDurham, US
Pieter Burger(Executive Officer, Director)Thomas Kaiser(Executive Officer, Director)
BoardChristopher Meldrum(Executive Officer, Director)inDennis Langer(Director)
Board seatJohn Hamer· per SEC Form D
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)Jim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesMPM BioImpactRA CapitalDeerfield Management Company
BiotechBoston, US
David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)Raymond Camahort(Director)
Co-investorsDCVC (Data Collective)Longwood FundNovo Holdings
NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.
Circular EconomyCleantechNew Materials
Co-investorsArc AngelsIcehouse VenturesLux CapitalThe Column Group
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtech
Co-investorsThe Column GroupLux Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.